Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.78 |
| ▸ | FAAH | O00519 | 3/20 | 0.78 |
| ▸ | ABHD16A | O95870 | 2/20 | 0.63 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.52 |
| ▸ | LPL | P06858 | 1/20 | 0.47 |
| ▸ | LIPC | P11150 | 1/20 | 0.47 |
| ▸ | LIPE | Q05469 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2233406 | 0.93 | ABHD16A (0.72) | MGLLFAAHABHD16ANPBWR1LPL | |
| SCHEMBL2853266 | 0.90 | MGLL (0.64) | MGLLFAAHABHD16ANPBWR1 | |
| SCHEMBL6552566 | 0.87 | MGLL (1.00) | MGLLFAAHABHD16A | |
| SCHEMBL7044899 | 0.86 | MGLL (0.59) | MGLLFAAHABHD16ANPBWR1LPL | |
| SCHEMBL7046287 | 0.84 | MGLL (0.57) | MGLLFAAHABHD16ANPBWR1 | |
| SCHEMBL2854103 | 0.82 | FAAH (0.53) | MGLLFAAHABHD16ANPBWR1 | |
| SCHEMBL2702430 | 0.80 | MGLL (0.52) | MGLLFAAHABHD16ANPBWR1LIPC | |
| SCHEMBL2235103 | 0.79 | ABHD16A (0.74) | MGLLFAAHABHD16ALPLLIPC | |
| SCHEMBL7044319 | 0.78 | ABHD16A (0.53) | MGLLFAAHABHD16ALPLLIPC | |
| SCHEMBL2233598 | 0.78 | ABHD16A (0.72) | MGLLFAAHABHD16ANPBWR1LPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | claimed |
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | AVENTIS PHARMA DEUTSCHLAND GMBH | 2003-12-25 | — | — | US | disclosed |
| US-6596742-B1 | Inhibitory effect on the hormone-sensitive lipase, HSL. insecticides, controlling metabolism and multistage synthesis | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236288-A1 | Use of substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadizol-2-ones for inhibiting pancreatic lipase | PNLIP, CEL, LIPE | MGLL 10/4885FAAH 142/4885ABHD16A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.